Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bensen

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|January 9, 2013
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activityMicheal Trzoss, Daniel C Bensen, Xiaoming Li, et al.
Cancer Discovery|January 26, 2021
TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through MerlinPedro Torres-Ayuso, Elvira An, Katherine M Nyswaner, et al.
Nature Microbiology|March 18, 2025
Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in miceSimon Döhrmann, James Levin, Jason N Cole, et al.
Plos One|January 4, 2014
Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agentsLeslie W Tari, Xiaoming Li, Michael Trzoss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinomaL Goyal, D DiToro, F Facchinetti, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|January 9, 2013
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activityMicheal Trzoss, Daniel C Bensen, Xiaoming Li, et al.
Cancer Discovery|January 26, 2021
TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through MerlinPedro Torres-Ayuso, Elvira An, Katherine M Nyswaner, et al.
Nature Microbiology|March 18, 2025
Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in miceSimon Döhrmann, James Levin, Jason N Cole, et al.
Plos One|January 4, 2014
Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agentsLeslie W Tari, Xiaoming Li, Michael Trzoss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinomaL Goyal, D DiToro, F Facchinetti, et al.
Pageof 3